Stryker Corporation (NYSE:SYK) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC reduced its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 32.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,271 shares of the medical technology company's stock after selling 1,588 shares during the quarter. Schechter Investment Advisors LLC's holdings in Stryker were worth $1,217,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Proficio Capital Partners LLC raised its stake in Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after purchasing an additional 523 shares during the last quarter. HBK Sorce Advisory LLC grew its position in Stryker by 16.8% during the fourth quarter. HBK Sorce Advisory LLC now owns 807 shares of the medical technology company's stock worth $291,000 after buying an additional 116 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in Stryker by 12.1% during the fourth quarter. Picton Mahoney Asset Management now owns 762 shares of the medical technology company's stock worth $275,000 after buying an additional 82 shares in the last quarter. Finally, Natixis Advisors LLC raised its position in Stryker by 16.9% in the fourth quarter. Natixis Advisors LLC now owns 184,817 shares of the medical technology company's stock worth $66,543,000 after purchasing an additional 26,730 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.20% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $389.24 on Monday. The stock has a fifty day moving average of $384.79 and a 200-day moving average of $377.20. The stock has a market cap of $148.57 billion, a PE ratio of 52.60, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same period in the prior year, the firm posted $2.50 earnings per share. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is presently 45.41%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Citigroup reissued a "buy" rating and issued a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Finally, Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $428.55.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.